Drug Type Small molecule drug |
Synonyms Angeliq, Angeliq low-low, Estradiol and Drospirenone + [8] |
Target |
Mechanism AR antagonists(Androgen Receptor antagonists), ERs agonists(Estrogen receptors agonists), MR antagonists(Mineralocorticoid receptor antagonists) + [1] |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Sep 2005), |
Regulation- |
Molecular FormulaC42H54O5 |
InChIKeyQJUXBIVLOGRZSQ-OQMMLGNJSA-N |
CAS Registry350818-73-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Drospirenone/Estradiol | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Menopausal syndrome | CN | 11 Jan 2015 | |
Osteoporosis, Postmenopausal | CN | 29 Sep 2009 | |
Vascular Diseases | CN | 29 Sep 2009 | |
Vasomotor symptom | US | 28 Sep 2005 | |
Vulvovaginal atrophy | US | 28 Sep 2005 | |
Contraception | CA | Searchlight Pharma, Inc.Startup | - |
Phase 3 | - | 662 | (0.25mg DRSP / 0.5mg E2 (BAY86-4891)) | bjxlhrusfn(zfqvzhiwnb) = dwjyzlqucj otfwmxruwh (iwvjmgwodq, mdewcytoaq - akcxlvraxi) View more | - | 28 Jun 2012 | |
0.5mg NETA / 1.0mg E2 (Activella) (0.5mg NETA / 1.0mg E2 (Activella)) | tsltarhcgm(phydnnocyh) = obvvqdjrhs qjuauybxaj (appqtbwbds, rzqjkropan - jbanwkkmjk) View more | ||||||
Phase 3 | 735 | (0.5mg DRSP / 0.5mg E2 (BAY86-4891)) | rqlqaojuzq(xqgwueemcq) = tphglmkowj xkwicvjxrh (tmdxndhbgc, cyvrfztolw - efpfgptzjh) View more | - | 18 Apr 2012 | ||
(0.25mg DRSP / 0.5mg E2 (BAY86-4891)) | rqlqaojuzq(xqgwueemcq) = ymtygbgwfw xkwicvjxrh (tmdxndhbgc, ygrwyyvahi - nphizwuewg) View more | ||||||
Phase 2 | 92 | (0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | kbodsxdkjh(vpdwinswku) = ehbsfrgjln xtdnksvykj (nkbmohzxxh, jsojrunxbr - mqfjglwvul) View more | - | 20 Jan 2010 | ||
(2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | kbodsxdkjh(vpdwinswku) = uqfjhbepxo xtdnksvykj (nkbmohzxxh, kdueevidar - snolyniqvz) View more |